Clinical observation of hepatoprotective agents for prevention of liver injury during initial chemotherapy of patients with acute myeloid leukemia / 中国药学杂志

ABSTRACT

OBJECTIVE: To investigate the preventive effect of hepatoprotective agents against liver injury induced by initial chemotherapy in patients with acute myeloid leukemia (AML). METHODS: A total of 128 patients with newly diagnosed AML in the department of hematology of one tertiary hospital who received IA regimen were enrolled into this study during the period of January 2012 to December 2015. Using a retrospective study design, differences were assessed between the group treated with hepatoprotective agents (experimental group; n = 99) and that withou hepatoprotective agents (control group; n = 29). The experimental group was further divided into four groups, ie, glutathione group, magnesium isoglycyrrhizinate group, glutathione combined with magnesium isoglycyrrhizinate group, and the other group. The patients in the experimental group were treated with hepatoprotective agents at the first time of inducing chemotherapy while the patients in the control group received inducing chemotherapy only. The biochemical indexes for liver function of all the patients were recorded. RESULTS: There was no significant difference in the incidence of liver injury between the experimental group and control group (P > 0.05), and the preventive effects in the three groups were similar (P > 0.05). Cox regression analysis of the related factors of the occurrence of liver injury showed that there was no significant difference (P > 0.05). CONCLUSION: Prophylactic use of hepatoprotective agents does not reduce the incidence of liver injury among treatment-naive patients with AML who have received IA regimen.